Financial Performance - Total net revenue for Q1 2025 was $52.6 million, an increase from $51.3 million in Q1 2024 [5][21] - MACI net revenue grew by 15% to $46.3 million compared to the previous year [5][7] - Burn Care net revenue was $6.3 million, comprising $5.0 million from Epicel and $1.3 million from NexoBrid [5] - Gross margin remained stable at 69% [8] - The net loss for the quarter was $11.2 million, or $0.23 per diluted share, compared to a net loss of $3.9 million, or $0.08 per diluted share, in Q1 2024 [10][21] - Non-GAAP adjusted EBITDA for the quarter was $3.2 million, down from $7.2 million in Q1 2024 [10][22] Business Highlights - Approximately 400 MACI Arthro surgeons have been trained to date, with a year-to-date biopsy growth exceeding 30% for these trained surgeons [5][4] - The company reported the second highest number of MACI biopsies and surgeons taking biopsies since the product launch, with March recording the highest number of biopsies in any month since launch [5] - NexoBrid revenue increased by 207% year-over-year and 31% quarter-over-quarter [5] - Epicel saw the highest number of biopsies in a quarter since 2023 during Q1 2025 [5] Future Guidance - The company expects second quarter total revenue and MACI revenue growth to be in the low- to mid-20% range [5][6] - Full-year 2025 revenue guidance has been reaffirmed, with expected growth of 20% to 23% [6] - Profitability guidance has been raised to a gross margin of 74% and an adjusted EBITDA margin of 26% for the full year [6]

“Creating an Attractive Entry Point to Advance Commercialization and Strengthen its National Scale-up Efforts.”WOODS CROSS, Utah, May 08, 2025 (GLOBE NEWSWIRE) -- Sky Quarry Inc. (NASDAQ: SKYQ) ("Sky Quarry" or "the Company"), an integrated energy solutions company committed to revolutionizing the waste asphalt shingle recycling industry, today announced that it has signed a non-binding Letter of Intent (LOI) with R & R Solutions Inc., the only permitted asphalt shingle recycler in New Mexico. The LOI repre ...

Core Insights - Stack Capital Group Inc. reported its financial results for Q1 2025, with a Book Value per Share (BVpS) of $12.06, down from $12.29 as of December 31, 2024 [4] - The Company made significant investments in various technology sectors, including AI, autonomous robotics, and travel, with notable portfolio companies such as CoreWeave, Shield AI, and Omio [4][6] Financial Performance - As of March 31, 2025, Stack Capital's total Book Value was $129.7 million [4] - The Company invested an additional US$2.2 million in CoreWeave prior to its IPO, which subsequently saw a share price increase of 45% from March 31, 2025, contributing an estimated $0.45 increase to the BVpS [4][6] - Shield AI raised US$240 million at a valuation of US$5.3 billion, enhancing its position within Stack Capital's portfolio [4] Portfolio Highlights - The breakdown of Book Value per Share as of March 31, 2025, includes: - SpaceX: $2.18 - Locus Robotics: $1.32 - Canva: $1.29 - Omio: $1.11 - Hopper: $1.07 - Newfront Insurance: $1.07 [3][5] - Following the quarter-end, SpaceX received FAA approval to increase its Starship launches to 25 per year, which is expected to benefit its Starlink satellite communications business [4] - Locus Robotics launched its 'Array' autonomous mobile robot, which significantly reduces manual labor in warehouse operations [4] Strategic Developments - Omio expanded its services into Southeast Asia, adding over 14,000 bus routes and aiming to become a comprehensive multi-modal travel provider by Q4 2025 [4] - The Company is focused on maximizing long-term performance through a diversified portfolio of high-growth businesses, which are not widely available to most Canadian investors [6]

Financial Results - Revenues for Q1-25 were $88,076, an increase of $1,472 or 2% compared to Q1-24, driven by growth in key promoted products, partially offset by declines in mature products and currency depreciation in select LATAM countries [7][13] - Gross margin decreased to $34,866 or 40% of revenues from $41,699 or 48% in the same period last year, primarily due to hyperinflation accounting in Argentina [7][19] - Operating loss was $5,537 compared to an operating income of $2,660 in Q1-24 [11][25] - Net income was $2,185, a significant improvement from a net loss of $4,546 in the prior year [25] - Adjusted revenues were $87,979, reflecting a 3% increase, and $6,631 or 8% on a constant currency basis [7][13] Corporate Developments - The company entered into an asset purchase agreement to acquire the Paladin business for $100,000, with an additional $20,000 for inventory, and potential future payments of up to $15,000 based on sales milestones [7][36] - A working capital line of credit of USD 40,000 was obtained from Citibank, with USD 35,000 withdrawn [6][37] - The company in-licensed Onicit IV for distribution in Mexico, Brazil, and select LATAM countries, and submitted Tavalisse for ANMAT approval in Argentina [8][33][35] Shareholder Updates - Shareholders re-elected members to the Board of Directors, including Jonathan Ross Goodman and Samira Sakhia [9] Financial Outlook - The company reaffirmed its financial guidance for 2025, expecting revenues between $390 million to $405 million and adjusted EBITDA to be approximately 13% of revenues [38]

MASH Resolution Index (MASHResInd) model highly predictive of MASH resolutionGAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution ...

Core Viewpoint - American Tungsten Corp. has appointed James Whittaker to its Board of Directors, replacing Adam Virani, who has resigned from the Board [1][4]. Group 1: Board Changes - James Whittaker brings over 35 years of global leadership experience in the mining and metals industry, enhancing the Board's capabilities [2][4]. - Adam Virani has been acknowledged for his valuable contributions and technical expertise during his tenure [1]. Group 2: Executive Background - Mr. Whittaker is currently the Chief Operating Officer for Capstone Copper, overseeing operations in Chile, the U.S., and Mexico [2]. - He previously served as President of Escondida for BHP, managing the world's largest copper operation, and has held senior roles at OceanaGold and Barrick [3]. Group 3: Company Overview - American Tungsten Corp. is involved in the acquisition and exploration of magnetite mineral properties, with significant projects including the Star Project and the IMA Mine Project [5]. - The Star Project covers approximately 4,615.75 hectares in British Columbia, while the IMA Mine Project is a past-producing underground tungsten mine located in Idaho [5].

Financial Highlights Q2 Performance Driven by Revenue Growth Across Recorded Music and Music PublishingCost Savings Plans on Track, With Reinvestment Initiatives AcceleratingYear-to-Date Operating Cash Flow and Free Cash Flow Increased by 53% and 59%, Respectively For the three months ended March 31, 2025 Total revenue decreased 1%, or increased 1% in constant currencyNet income decreased 63% to $36 million versus $96 million in the prior-year quarterOperating income increased 41% to $168 million versus $11 ...

NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2025. "Overall revenue of $16.7 million in the first quarter exceeded our expectations, reflecting year-over-year total revenue growth of 28%, primarily driven by higher professional services r ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongo ...

WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, ...